AVEO Pharmaceuticals, Inc.
AVEO
AVEO was delisted on the 19th of January, 2023.
63 hedge funds and large institutions have $57.7M invested in AVEO Pharmaceuticals, Inc. in 2020 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 22 increasing their positions, 15 reducing their positions, and 15 closing their positions.
47% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 15
22% more call options, than puts
Call options by funds: $7.03M | Put options by funds: $5.76M
0% more capital invested
Capital invested by funds: $57.6M → $57.7M (+$59.4K)
3% less funds holding
Funds holding: 65 → 63 (-2)
13% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$3.39M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$409K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$332K |
| 4 |
PP
PDT Partners
New York
|
+$306K |
| 5 |
State Street
Boston,
Massachusetts
|
+$294K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$1.84M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$1.79M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$1.73M |
| 4 |
6CM
683 Capital Management
New York
|
-$1.73M |
| 5 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$1.29M |
AVEO Hedge Fund Activity: Q3 2020 in Review
63 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals, Inc. (AVEO) for Q3 2020, worth a combined $57.7M — up 0.1% from $57.6M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of AVEO and 13 opened new positions — a net loss of 2 holders — while 15 trimmed existing stakes and 22 added.
The largest buyer was BlackRock, adding an estimated $3.39M. The largest seller was Deerfield Management, exiting entirely with an estimated $1.84M sold.
- 63 institutional investors held AVEO Pharmaceuticals, Inc. (AVEO) as of Q3 2020, down from 65 in Q2 2020.
- Funds reported $57.7M of AVEO Pharmaceuticals, Inc. stock for Q3 2020, up 0.1% quarter-over-quarter.
- 13 funds opened new AVEO Pharmaceuticals, Inc. positions in Q3 2020 and 15 closed out, a net change of -2 holders.
- The largest AVEO Pharmaceuticals, Inc. buyer in Q3 2020 was BlackRock, an estimated $3.39M added.
- The largest AVEO Pharmaceuticals, Inc. seller in Q3 2020 was Deerfield Management, an estimated $1.84M sold.
Based on aggregated 13F filings for Q3 2020.